Profile of lebrikizumab and its potential in the treatment of asthma

References

• ToTStanojevicSMooresGGlobal asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health20121220422429515
   PubMed Web of Science ®Google Scholar
• SadatsafaviMRousseauRChenWZhangWLyndLFitzGeraldJMThe preventable burden of productivity loss due to suboptimal asthma control: a population-based studyChest2014145478779324337140
   PubMed Web of Science ®Google Scholar
• ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• LinTYPoonAHHamidQAsthma phenotypes and endotypesCurr Opin Pulm Med2013191182323114560
   PubMed Web of Science ®Google Scholar
• HumbertMBusseWHananiaNAOmalizumab in asthma: an update on recent developmentsJ Allergy Clin Immunol Pract201425525. e536. e25213045
   PubMed Web of Science ®Google Scholar
• BousquetJCabreraPBerkmanNThe effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy200560330230815679714
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJSIRIUS InvestigatorsOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMENSA InvestigatorsMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• Wills-KarpMLuyimbaziJXuXInterleukin- 13: central mediator of allergic asthmaScience1998282225822619856949
   PubMed Web of Science ®Google Scholar
• GrünigGWarnockMWakilAERequirement for IL-13 independently of IL-4 in experimental asthmaScience19982825397226122639856950
   PubMed Web of Science ®Google Scholar
• BrandtEBZimmermannNMuntelEEThe alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestineClin Exp Allergy200636454355316630161
   PubMed Web of Science ®Google Scholar
• ZhuZHomerRJWangZPulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin productionJ Clin Invest1999103677978810079098
   PubMed Web of Science ®Google Scholar
• Van der Pouw KraanTCVan der ZeeJSBoeijeLCDe GrootERStapelSOAardenLAThe role of IL-13 in IgE synthesis by allergic asthma patientsClin Exp Immunol199811111291359472672
   PubMed Web of Science ®Google Scholar
• Fichtner-FeiglSStroberWKawakamiKPuriRKKitaniAIL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosisNat Med20061219910616327802
   PubMed Web of Science ®Google Scholar
• IzuharaKArimaKOhtaSSuzukiSInamitsuMYamamotoKPeriostin in allergic inflammationAllergol Int201463214315124662806
   PubMed Web of Science ®Google Scholar
• YuyamaNDaviesDEAkaiwaMAnalysis of novel disease-related genes in bronchial asthmaCytokine200219628729612421571
   PubMed Web of Science ®Google Scholar
• NorrisRADamonBMironovVPeriostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissuesJ Cell Biochem2007101369571117226767
   PubMed Web of Science ®Google Scholar
• SidhuSSYuanSInnesALRoles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthmaProc Natl Acad Sci U S A201010732141701417520660732
   PubMed Web of Science ®Google Scholar
• ParulekarADAtikMAHananiaNAPeriostin, a novel biomarker of TH2-driven asthmaCurr Opin Pulm Med2014201606524247042
   PubMed Web of Science ®Google Scholar
• JiaGEricksonRWChoyDFPeriostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patientsJ Allergy Clin Immunol20121303647654.e1022857879
   PubMed Web of Science ®Google Scholar
• TakayamaGArimaKKanajiTPeriostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signalsJ Allergy Clin Immunol200611819810416815144
   PubMed Web of Science ®Google Scholar
• WoodruffPGBousheyHADolganovGMGenome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProc Natl Acad Sci U S A200710440158581586317898169
   PubMed Web of Science ®Google Scholar
• WoodruffPGModrekBChoyDFT-helper type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med2009180538839519483109
   PubMed Web of Science ®Google Scholar
• CorrenJLemanskeRFHananiaNALebrikizumab treatment in adults with asthmaN Engl J Med2011365121088109821812663
   PubMed Web of Science ®Google Scholar
• NoonanMKorenblatPMosesovaSDose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsJ Allergy Clin Immunol20131323567. e574. e23726041
   PubMed Web of Science ®Google Scholar
• ScheerensHArronJRZhengYThe effects of lebrikizumab in patients with mild asthma following whole lung allergen challengeClin Exp Allergy2014441384624131304
   PubMed Web of Science ®Google Scholar
• InmanMDWatsonRCockcroftDWWongBJHargreaveFEO’ByrnePMReproducibility of allergen-induced early and late asthmatic responsesJ Allergy Clin Immunol1995956119111957797787
   PubMed Web of Science ®Google Scholar
• GauvreauGMWatsonRMRerecichTJRepeatability of allergen-induced airway inflammationJ Allergy Clin Immunol19991041667110400841
   PubMed Web of Science ®Google Scholar
• HananiaNANoonanMJCorrenJEfficacy and safety of lebrikizumab in severe uncontrolled asthma: results from the lute and verse phase II randomized, double-blind, placebo-controlled trialsJ Allergy Clin Immunol20141332AB402
   Web of Science ®Google Scholar
• BlanchardCMishraASaito-AkeiHMonkPAndersonIRothenbergMEInhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)Clin Exp Allergy20053581096110316120093
   PubMed Web of Science ®Google Scholar
• MayRDMonkPDCohenESPreclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthmaBr J Pharmacol2012166117719321895629
   PubMed Web of Science ®Google Scholar
• PiperEBrightlingCNivenRA phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEur Respir J201341233033822743678
   PubMed Web of Science ®Google Scholar
• JovaniMFiorinoGDaneseSAnti-IL-13 in inflammatory bowel disease: from the bench to the bedsideCurr Drug Targets201314121444145223746199
   PubMed Web of Science ®Google Scholar
• DaneseSRudzińskiJBrandtWTralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa studyGut201564224324925304132
   PubMed Web of Science ®Google Scholar
• KasaianMTTanXYJinMInterleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeysJ Pharmacol Exp Ther2008325388289218337474
   PubMed Web of Science ®Google Scholar
• HuaFRibbingJReinischWCataldiFMartinSA pharmacokinetic comparison of Anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patientsBr J Clin Pharmacol Epub2015122
   Web of Science ®Google Scholar
• ReinischWPanésJKhuranaSAnrukinzumab, an anti- interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyGut201564689490025567115
   PubMed Web of Science ®Google Scholar
• De BoeverEHAshmanCCahnAPEfficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trialJ Allergy Clin Immunol2014133498999624582316
   PubMed Web of Science ®Google Scholar
• SteinkeJWAnti-interleukin-4 therapyImmunol Allergy Clin North Am200424459961415474861
   PubMed Web of Science ®Google Scholar
• HartTKBlackburnMNBrigham-BurkeMPreclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthmaClin Exp Immunol200213019310012296858
   PubMed Web of Science ®Google Scholar
• WenzelSFordLPearlmanDDupilumab in persistent asthma with elevated eosinophil levelsN Engl J Med2013368262455246623688323
   PubMed Web of Science ®Google Scholar
• BeckLAThaçiDHamiltonJDDupilumab treatment in adults with moderate-to-severe atopic dermatitisN Engl J Med2014371213013925006719
   PubMed Web of Science ®Google Scholar
• WenzelSWilbrahamDFullerRGetzEBLongphreMEffect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studiesLancet200737095961422143117950857
   PubMed Web of Science ®Google Scholar
• SlagerREOtulanaBAHawkinsGAIL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to anti-IL-4 receptor a antagonistJ Allergy Clin Immunol2012130251652222541248
   PubMed Web of Science ®Google Scholar